Abstract
Objectives:
Options for the treatment of well-differentiated neuroendocrine tumors (NETs) are limited. We evaluated the efficacy of capecitabine and temozolomide combination in patients from Jordan.
Methods:
A retrospective review was conducted of 21 patients with metastatic well-differentiated NETs who failed somatostatin analogues and chemotherapy. Patients received capecitabine and temozolomide regimen every 28 days, and evaluation was done every 2 cycles.
Results:
Twelve patients (57%) achieved partial response, and 5 (23%) achieved stable disease. Median progression-free survival was 16.5 months (range, 14.8-18 months). Of the 7 carcinoid tumors, 2 had partial response, and 2 had stable disease. There were no grade 4 toxicities or treatment-related deaths.
Conclusions:
Capecitabine and temozolomide regimen is an effective and well-tolerated salvage option for well-differentiated NETs.
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Capecitabine
-
Carcinoid Tumor / drug therapy
-
Carcinoid Tumor / epidemiology
-
Cell Differentiation
-
Dacarbazine / administration & dosage
-
Dacarbazine / analogs & derivatives
-
Deoxycytidine / administration & dosage
-
Deoxycytidine / analogs & derivatives
-
Developing Countries
-
Disease-Free Survival
-
Female
-
Fluorouracil / administration & dosage
-
Fluorouracil / analogs & derivatives
-
Gastrointestinal Neoplasms / drug therapy*
-
Gastrointestinal Neoplasms / epidemiology
-
Humans
-
Jordan / epidemiology
-
Male
-
Middle Aged
-
Neuroendocrine Tumors / drug therapy*
-
Neuroendocrine Tumors / epidemiology
-
Neuroendocrine Tumors / pathology
-
Neuroendocrine Tumors / secondary*
-
Remission Induction
-
Retrospective Studies
-
Salvage Therapy
-
Temozolomide
-
Treatment Outcome
Substances
-
Deoxycytidine
-
Capecitabine
-
Dacarbazine
-
Fluorouracil
-
Temozolomide